Vaccines

Study finds delaying vaccines is risky

Study finds delaying vaccines is risky

By

A study shows that veering off the recommended vaccination schedule ups the risk for childhood seizures.

CDC: un-vaccinated behind measles outbreak

The CDC said Thursday that most of the 288 recent US measles cases were caused by un-vaccinated travelers who brought the virus home with them.

GSK, Novartis, Lilly play musical chairs

GSK, Novartis, Lilly play musical chairs

By

The three drugmakers rearranged part of the pharma universe Tuesday with a string of pipeline-altering deals.

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

Study: Anti-vaxxers immune to PSAs

Researchers find public service announcements and physician information don't change minds, but a California practice found one way it could.

Prevnar 13 hits goals, but impact is uncertain

Prevnar 13 hits goals, but impact is uncertain

By

Pfizer hit its endpoints for preventing pneumonia among the elderly, but the data may not be robust enough to spur vaccination.

Study shows HPV vax impact

Queensland, Australia, researchers find the risk of high-grade cervical abnormalities fell 46% among women who had received all three doses of the HPV vaccine.

Doctors say vaccines don't pay

Ten percent of surveyed doctors told the Centers for Disease Control that reimbursement rates are not enough.

Pfizer Prevnar data could boost Rx numbers

Pfizer Prevnar data could boost Rx numbers

By

The drugmaker revealed efficacy data that analysts say could prompt the health agencies to emphasize adult vaccination.

Merck sends HPV vax to FDA

Merck sends HPV vax to FDA

By

The drugmaker's new vaccine has more brawn, but vaccination rates among boys and girls remain low.

Panel urges increased HPV vaccination rates

Hitting a vaccination rate of 80% of girls would mean 53,000 fewer cases of cervical cancer.

Lilly primes investors for possible cuts

Lilly primes investors for possible cuts

By

Echoing a strategy similar to that posed by Merck, the drug maker told investors that its strategy for hitting revenue targets includes efficiencies. It also depends on a regulatory-friendly pipeline.

Shutdown dims lights at FDA, NIH and CDC

Shutdown dims lights at FDA, NIH and CDC

By

The midnight shutdown put 800,000 government employees on leave, including those at the FDA, NIH and CDC.

Merck reorg reimagines sales force

Merck reorg reimagines sales force

By

The company will "fill the bag" of its sales reps, as part of a reorganization that also includes 8,500 job cuts and a more refined R&D focus.

Kleenex brand goes flu hunting

Kleenex brand goes flu hunting

By

The Kimberly-Clark-backed cold and flu predictor mixes Big Data, and big branding, with an individualized focus.

GSK clears another flu vaccine, but patients may not be buying

GSK clears another flu vaccine, but patients may not be buying

By

The FDA approved GlaxoSmithKline's second quadrivalent flu vaccine, but a CVS study indicates that consumers are big fans of the vaccination, as long as they aren't the ones rolling up their sleeves.

Business briefs: GSK, Otsuka, Roche and Gilead

GSK seeks a new ovarian cancer indication for Votrient; a bill that would extend exclusivity for some combination drugs is introduced in Congress; Otsuka's tolvaptan gets a thumbs-down from an FDA advisory committee; NICE rejects Roche's Perjeta; India tosses Herceptin patents; and China revokes Gilead's patent on Viread

Merck braces for revenue shortfall amid patent losses

By

Quarterly sales fell 11% compared to the same period last year. The company plans on weathering a continued flow of patent losses with a narrower R&D focus.

HPV vaccination rates losing ground, CDC reports

By

The CDC says HPV vaccination rates are not improving. The latest data comes just as a recent report shows the vaccine cannot only help fend off cervical cancer, but throat cancers as well.

Business briefs: Teva, AbbVie, Novartis, Wockhardt

FDA grants Teva three years exclusivity to sell Plan B OTC for all ages; FDA gives Humira a thumbs-down for spondyloarthritis; a UK vaccine committee rejects Novartis' meningitis B shot; and Wockhardt gets a warning letter from FDA for its manufacturing practices at an Indian plant.

GSK breaks cloud cover with financial results

GSK breaks cloud cover with financial results

By

GlaxoSmithKline second-quarter sales rose 2% over the same period last year. CEO Andrew Witty says it is too early to tally the impact of China's corruption allegations.

Business briefs: GSK, Incyte, Pfizer, plus EU's R&D hike

China alleges GSK foul play; a report links Incyte's Jakafi with PML; Pfizer gets a double-dose of good Prevnar news; Europe puts almost $29B toward research.

Business briefs: GSK and Sanofi, plus state legislative news

GlaxoSmithKline says it is scaling back on acquisitions; Sanofi's CEO picks a regulatory fight; Maine wants to allow Ex-US meds; and New York State seeks to empower pharmacists.

Business briefs: Novo Nordisk, Eli Lilly, Merck

Analysts say Novo Nordisk's Victoza should brace for Eli Lilly competition; Lilly halts an Alzheimer's study; and Japan reverses its HPV vaccination stance.

Business Briefs: Amgen and Astellas; GSK; Teva; Novo; Livestrong

Amgen and Astellas team up to take on Japan; GSK acquires Swiss vaccine developer's innovative platform; Ireland makes generic switches easier; Novo backs wet AMD therapy; Nike ditches Livestrong

It's Consumer's Choices as Guidelines Change

It's Consumer's Choices as Guidelines Change

Welcome to the ambivalent world of healthcare, where confusion reigns as shifts in science and guidelines seemingly raise more questions than they answer.

Late-season flu peak hits vax slackers

By

Nearly a quarter of respondents to an MDLinx poll of 2,400 doctors said this flu season is the worst they've seen, and pharmacies are being deluged with a late-season run on vaccines.

Egg-free, mercury-free flu vaccine approved

By

The FDA approved a flu vaccine that can be produced quickly, and lacks many elements that make patients skittish.

Company news: Galderma, UCB, GSK

Galderma expands its surface area, UCB celebrates RA victories online and GSK pilots a vaccine communications program in Mozambique.

Company news: Pfizer, CVS, Challenger Gray

Pfizer is diving into the (stem cell) banking business, CVS turns app into vaccine scheduler, Challenger crunches layoff numbers.

Email Newsletters